Eli Lilly, Lilly, olomorasib, KRAS G12C, non-small cell lung cancer, NSCLC, SUNRAY-01, LOXO-RAS-20001, pembrolizumab, KEYTRUDA, chemoimmunotherapy, targeted therapy

Indianapolis, Indiana, U.S., October 25, 2026 Eli Lilly and Company announced updated clinical findings for olomorasib, its investigational next-generation...